{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:40:11Z","timestamp":1790707211426,"version":"4.1.0"},"reference-count":94,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Intramural Research Program of National Institute of Neurological Disorders"},{"DOI":"10.13039\/100000002","name":"Stroke, National Institutes of Health","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Virology"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.coviro.2020.02.005","type":"journal-article","created":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T17:30:20Z","timestamp":1586453420000},"page":"19-27","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Checkpoint inhibitors for the treatment of JC virus-related progressive multifocal leukoencephalopathy"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7839-7958","authenticated-orcid":false,"given":"Erin S","family":"Beck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Cortese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coviro.2020.02.005_sbref0005","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S1474-4422(18)30040-1","article-title":"Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned","volume":"17","author":"Major","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.coviro.2020.02.005_bib0010","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1474-4422(10)70040-5","article-title":"Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis","volume":"9","author":"Tan","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.coviro.2020.02.005_bib0015","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.meegid.2017.06.011","article-title":"Biology, evolution, and medical importance of polyomaviruses: an update","volume":"54","author":"Moens","year":"2017","journal-title":"Infect Genet Evol"},{"key":"10.1016\/j.coviro.2020.02.005_bib0020","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/jmv.10450","article-title":"Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40","volume":"71","author":"Knowles","year":"2003","journal-title":"J Med Virol"},{"key":"10.1016\/j.coviro.2020.02.005_bib0025","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1086\/514032","article-title":"Analysis of the systemic and intrathecal humoral immune response in progressive multifocal leukoencephalopathy","volume":"176","author":"Weber","year":"1997","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2020.02.005_bib0030","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1093\/infdis\/127.4.467","article-title":"Prevalence of antibodies in human sera against JC virus, an isolate from a case of progressive multifocal leukoencephalopathy","volume":"127","author":"Padgett","year":"1973","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2020.02.005_bib0035","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.imbio.2018.01.002","article-title":"Progressive multifocal leukoencephalopathy consortium. T cell deficiencies as a common risk factor for drug associated progressive multifocal leukoencephalopathy","volume":"223","author":"Pavlovic","year":"2018","journal-title":"Immunobiology"},{"key":"10.1016\/j.coviro.2020.02.005_bib0040","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1128\/CMR.05031-11","article-title":"Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain","volume":"25","author":"Ferenczy","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.coviro.2020.02.005_bib0045","doi-asserted-by":"crossref","first-page":"197807","DOI":"10.1155\/2013\/197807","article-title":"Polyomavirus JC in the context of immunosuppression: a series of adaptive, DNA replication-driven recombination events in the development of progressive multifocal leukoencephalopathy","volume":"2013","author":"Johnson","year":"2013","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.coviro.2020.02.005_bib0050","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/ana.24371","article-title":"Persistence and pathogenesis of the neurotropic polyomavirus JC","volume":"77","author":"Wollebo","year":"2015","journal-title":"Ann Neurol"},{"key":"10.1016\/j.coviro.2020.02.005_bib0055","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0733-8619(18)31105-8","article-title":"Progressive multifocal leukoencephalopathy","volume":"2","author":"Brooks","year":"1984","journal-title":"Neurol Clin"},{"issue":"Suppl. 1(s1)","key":"10.1016\/j.coviro.2020.02.005_bib0060","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1080\/13550280390195261","article-title":"Progressive multifocal leukoencephalopathy in acquired immunodeficiency syndrome: explaining the high incidence and disproportionate frequency of the illness relative to other immunosuppressive conditions","volume":"9","author":"Berger","year":"2003","journal-title":"J Neurovirol"},{"key":"10.1016\/j.coviro.2020.02.005_bib0065","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1056\/NEJMoa051847","article-title":"Progressive multifocal leukoencephalopathy in a patient treated with natalizumab","volume":"353","author":"Langer-Gould","year":"2005","journal-title":"New Engl J Med"},{"key":"10.1016\/j.coviro.2020.02.005_bib0070","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1056\/NEJMoa051782","article-title":"Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis","volume":"353","author":"Kleinschmidt-DeMasters","year":"2005","journal-title":"New Engl J Med"},{"key":"10.1016\/j.coviro.2020.02.005_bib0075","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1056\/NEJMoa051586","article-title":"Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn\u2019s disease","volume":"353","author":"Van Assche","year":"2005","journal-title":"New Engl J Med"},{"key":"10.1016\/j.coviro.2020.02.005_bib0080","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.1128\/JVI.75.7.3483-3487.2001","article-title":"JC virus-specific cytotoxic T lymphocytes in individuals with progressive multifocal leukoencephalopathy","volume":"75","author":"Koralnik","year":"2001","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2020.02.005_bib0085","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1080\/13550280152537175","article-title":"JCV-specific cellular immune response correlates with a favorable clinical outcome in HIV-infected individuals with progressive multifocal leukoencephalopathy","volume":"7","author":"Du Pasquier","year":"2001","journal-title":"J Neurovirol"},{"key":"10.1016\/j.coviro.2020.02.005_bib0090","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1093\/brain\/awh215","article-title":"A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy","volume":"127","author":"Du Pasquier","year":"2004","journal-title":"Brain"},{"key":"10.1016\/j.coviro.2020.02.005_bib0095","doi-asserted-by":"crossref","first-page":"7256","DOI":"10.1128\/JVI.02506-10","article-title":"Role of CD4+ and CD8+ T-cell responses against JC virus in the outcome of patients with progressive multifocal leukoencephalopathy (PML) and PML with immune reconstitution inflammatory syndrome","volume":"85","author":"Gheuens","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2020.02.005_bib0100","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1093\/brain\/awr206","article-title":"Central role of JC virus-specific CD4+ lymphocytes in progressive multi-focal leucoencephalopathy-immune reconstitution inflammatory syndrome","volume":"134","author":"Aly","year":"2011","journal-title":"Brain"},{"key":"10.1016\/j.coviro.2020.02.005_bib0105","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/ana.24574","article-title":"Mechanisms of immune escape in central nervous system infection with neurotropic JC virus variant","volume":"79","author":"Jelcic","year":"2016","journal-title":"Ann Neurol"},{"key":"10.1016\/j.coviro.2020.02.005_bib0110","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/ana.20933","article-title":"Progressive multifocal leukoencephalopathy revisited: has the disease outgrown its name?","volume":"60","author":"Koralnik","year":"2006","journal-title":"Ann Neurol"},{"key":"10.1016\/j.coviro.2020.02.005_bib0115","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1212\/01.wnl.0000343510.08643.74","article-title":"PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids","volume":"72","author":"Tan","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.coviro.2020.02.005_bib0120","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1212\/WNL.0b013e31822e55e7","article-title":"Immune reconstitution inflammatory syndrome in natalizumab-associated PML","volume":"77","author":"Tan","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.coviro.2020.02.005_bib0125","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1212\/WNL.0b013e31821a446b","article-title":"Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"76","author":"Vermersch","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.coviro.2020.02.005_bib0130","first-page":"1374","article-title":"Progressive multifocal leukoencephalopathy","volume":"18","author":"Aksamit","year":"2012","journal-title":"Continuum (Minneap Minn)"},{"key":"10.1016\/j.coviro.2020.02.005_bib0135","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10096-013-1941-6","article-title":"Continued declining incidence and improved survival of progressive multifocal leukoencephalopathy in HIV\/AIDS patients in the current era","volume":"33","author":"Casado","year":"2014","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.coviro.2020.02.005_bib0140","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3109\/13550289809113482","article-title":"Progressive multifocal leukoencephalopathy in patients with HIV infection","volume":"4","author":"Berger","year":"1998","journal-title":"J Neurovirol"},{"key":"10.1016\/j.coviro.2020.02.005_bib0145","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/13550280390195388","article-title":"Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: data from the Italian Registry Investigative Neuro AIDS (IRINA)","volume":"9 Suppl 1","author":"Antinori","year":"2003","journal-title":"J Neurovirol"},{"key":"10.1016\/j.coviro.2020.02.005_bib0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0020967","article-title":"Improved survival of HIV-1-infected patients with progressive multifocal leukoencephalopathy receiving early 5-drug combination antiretroviral therapy. Kaul R, editor","volume":"6","author":"Gasnault","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2020.02.005_bib0155","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/hiv.12008","article-title":"Evaluation of progressive multifocal leukoencephalopathy treatments in a Spanish cohort of HIV-infected patients: do protease inhibitors improve survival regardless of central nervous system penetration-effectiveness (CPE) score?","volume":"14","author":"Fanjul","year":"2013","journal-title":"HIV Med"},{"key":"10.1016\/j.coviro.2020.02.005_bib0160","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1089\/aid.2018.0232","article-title":"Not a disease of the past: a case series of progressive multifocal leukoencephalopathy in the established antiretroviral era","volume":"35","author":"Summers","year":"2019","journal-title":"AIDS Res Hum Retrov"},{"key":"10.1016\/j.coviro.2020.02.005_bib0165","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1093\/cid\/civ1220","article-title":"Progressive multifocal leukoencephalopathy in primary immune deficiencies: stat1 gain of function and review of the literature","volume":"62","author":"Zerbe","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coviro.2020.02.005_bib0170","doi-asserted-by":"crossref","first-page":"965","DOI":"10.2169\/internalmedicine.54.2308","article-title":"Rituximab-associated progressive multifocal leukoencephalopathy derived from non-Hodgkin lymphoma: neuropathological findings and results of mefloquine treatment","volume":"54","author":"Sano","year":"2015","journal-title":"Intern Med"},{"key":"10.1016\/j.coviro.2020.02.005_bib0175","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/bloodadvances.2017008201","article-title":"Progressive multifocal leukoencephalopathy and hematologic malignancies: a single cancer center retrospective review","volume":"1","author":"Neil","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.coviro.2020.02.005_sbref0180","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1146\/annurev-immunol-041015-055318","article-title":"CD8 T cell exhaustion during chronic viral infection and cancer","volume":"37","author":"McLane","year":"2019","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.coviro.2020.02.005_bib0185","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.coviro.2020.02.005_sbref0190","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nri.2017.112","article-title":"Immune checkpoint blockade in infectious diseases","volume":"18","author":"Wykes","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.coviro.2020.02.005_bib0195","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1093\/infdis\/jir820","article-title":"Mycobacterium tuberculosis promotes regulatory T-cell expansion via induction of programmed death-1 ligand 1 (PD-L1, CD274) on dendritic cells","volume":"205","author":"Trinath","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2020.02.005_bib0200","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1146\/annurev-immunol-032414-112049","article-title":"Coinhibitory pathways in immunotherapy for cancer","volume":"34","author":"Baumeister","year":"2016","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.coviro.2020.02.005_bib0205","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.coviro.2020.02.005_bib0210","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"New Engl J Med"},{"key":"10.1016\/j.coviro.2020.02.005_bib0215","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"New Engl J Med"},{"key":"10.1016\/j.coviro.2020.02.005_bib0220","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1073\/pnas.0830997100","article-title":"Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients","volume":"100","author":"Hodi","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2020.02.005_sbref0225","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1146\/annurev-med-012017-043208","article-title":"CD8 T cell exhaustion in chronic infection and cancer: opportunities for interventions","volume":"69","author":"Hashimoto","year":"2018","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.coviro.2020.02.005_bib0230","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.immuni.2016.07.021","article-title":"T cell factor 1-expressing memory-like CD8(+) T cells sustain the immune response to chronic viral infections","volume":"45","author":"Utzschneider","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.coviro.2020.02.005_bib0235","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nature19330","article-title":"Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy","volume":"537","author":"Im","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2020.02.005_bib0240","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/nature19317","article-title":"Follicular CXCR5- expressing CD8(+) T cells curtail chronic viral infection","volume":"537","author":"He","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2020.02.005_bib0245","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.immuni.2018.12.021","article-title":"Intratumoral Tcf1+PD-1+CD8+ T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy","volume":"50","author":"Siddiqui","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.coviro.2020.02.005_bib0250","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.immuni.2018.11.014","article-title":"Checkpoint blockade immunotherapy induces dynamic changes in PD-1-CD8+ tumor-infiltrating T cells","volume":"50","author":"Kurtulus","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.coviro.2020.02.005_bib0255","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/nature05115","article-title":"PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression","volume":"443","author":"Day","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2020.02.005_bib0260","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.molimm.2007.07.038","article-title":"PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients","volume":"45","author":"Peng","year":"2008","journal-title":"Mol Immunol"},{"key":"10.1016\/j.coviro.2020.02.005_bib0265","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0047648","article-title":"Upregulation of the Tim-3\/galectin-9 pathway of T cell exhaustion in chronic hepatitis B virus infection. Shoukry NH, editor","volume":"7","author":"Nebbia","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2020.02.005_bib0270","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.jhep.2014.07.005","article-title":"Restoration of HBV-specific CD8+ T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation","volume":"61","author":"Bengsch","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2020.02.005_bib0275","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1038\/nm1482","article-title":"Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction","volume":"12","author":"Trautmann","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.coviro.2020.02.005_bib0280","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005349","article-title":"TIGIT marks exhausted t cells, correlates with disease progression, and serves as a target for immune restoration in HIV and SIV infection. Silvestri G, editor","volume":"12","author":"Chew","year":"2016","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2020.02.005_bib0285","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.3892\/mmr.2016.5396","article-title":"CD28 family of receptors on T cells in chronic HBV infection: expression characteristics, clinical significance and correlations with PD-1 blockade","volume":"14","author":"Tang","year":"2016","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.coviro.2020.02.005_bib0290","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1084\/jem.20061496","article-title":"PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection","volume":"203","author":"Petrovas","year":"2006","journal-title":"J Exp Med"},{"key":"10.1016\/j.coviro.2020.02.005_bib0295","doi-asserted-by":"crossref","first-page":"4671","DOI":"10.1182\/blood-2006-09-044826","article-title":"PD-1 up-regulation is correlated with HIV-specific memory CD8+ T-cell exhaustion in typical progressors but not in long-term nonprogressors","volume":"109","author":"Zhang","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.coviro.2020.02.005_bib0300","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1128\/JVI.02844-06","article-title":"Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection","volume":"81","author":"Boni","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2020.02.005_bib0305","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.4254\/wjh.v7.i23.2449","article-title":"Programmed death-1\/programmed death-L1 signaling pathway and its blockade in hepatitis C virus immunotherapy","volume":"7","author":"Salem","year":"2015","journal-title":"World J Hepatol"},{"key":"10.1016\/j.coviro.2020.02.005_bib0310","doi-asserted-by":"crossref","first-page":"15001","DOI":"10.1073\/pnas.1312772110","article-title":"Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1)","volume":"110","author":"Fuller","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2020.02.005_bib0315","article-title":"The expression of PD-1 ligands and their involvement in regulation of T cell functions in acute and chronic woodchuck hepatitis virus infection. Wang F-S, editor","volume":"6","author":"Zhang","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2020.02.005_bib0320","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0063818","article-title":"A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection. Ahlenstiel G, editor","volume":"8","author":"Gardiner","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2020.02.005_sbref0325","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.jhep.2019.06.028","article-title":"Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: a pilot study","volume":"71","author":"Gane","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2020.02.005_bib0330","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S1473-3099(16)30541-2","article-title":"Nivolumab plus interferon-\u03b3 in the treatment of intractable mucormycosis","volume":"17","author":"Grimaldi","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.coviro.2020.02.005_bib0335","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1084\/jem.20121015","article-title":"Programmed death 1 protects from fatal circulatory failure during systemic virus infection of mice","volume":"209","author":"Frebel","year":"2012","journal-title":"J Exp Med"},{"key":"10.1016\/j.coviro.2020.02.005_bib0340","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002504","article-title":"The CTLA-4 and PD-1\/PD-L1 inhibitory pathways independently regulate host resistance to Plasmodium-induced acute immune pathology. Wherry EJ, editor","volume":"8","author":"Hafalla","year":"2012","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2020.02.005_bib0345","doi-asserted-by":"crossref","first-page":"13402","DOI":"10.1073\/pnas.1007394107","article-title":"Programmed death-1 (PD-1)-deficient mice are extraordinarily sensitive to tuberculosis","volume":"107","author":"L\u00e1z\u00e1r-Moln\u00e1r","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2020.02.005_sbref0350","first-page":"S95","author":"Redelman-Sidi","year":"2018"},{"key":"10.1016\/j.coviro.2020.02.005_bib0355","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1093\/cid\/ciw539","article-title":"The spectrum of serious infections among patients receiving immune checkpoint blockade for the treatment of melanoma","volume":"63","author":"Del Castillo","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coviro.2020.02.005_bib0360","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1097\/QAD.0000000000001599","article-title":"Hepatitis B reactivation in a long-term nonprogressor due to nivolumab therapy","volume":"31","author":"Lake","year":"2017","journal-title":"AIDS"},{"key":"10.1016\/j.coviro.2020.02.005_bib0365","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/s41591-019-0523-2","article-title":"A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis","volume":"25","author":"Johnson","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.coviro.2020.02.005_bib0370","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3389\/fonc.2019.00659","article-title":"Tuberculosis infection in a patient treated with nivolumab for non-small cell lung cancer: case report and literature review","volume":"9","author":"van Eeden","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.coviro.2020.02.005_bib0375","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jneuroim.2009.11.013","article-title":"Unmasking of PML by HAART: unusual clinical features and the role of IRIS","volume":"219","author":"Sidhu","year":"2010","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.coviro.2020.02.005_bib0380","doi-asserted-by":"crossref","first-page":"577","DOI":"10.3389\/fimmu.2017.00577","article-title":"Immune reconstitution inflammatory syndrome unmasking or worsening AIDS-related progressive multifocal leukoencephalopathy: a literature review","volume":"8","author":"Fournier","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.coviro.2020.02.005_bib0385","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.3389\/fimmu.2019.02060","article-title":"Immunotherapy in people with HIV and cancer","volume":"10","author":"Puronen","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.coviro.2020.02.005_bib0390","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/QAI.0b013e31825a313c","article-title":"Increased program cell death-1 expression on T lymphocytes of patients with progressive multifocal leukoencephalopathy","volume":"60","author":"Tan","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.coviro.2020.02.005_sbref0395","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa1815039","article-title":"Pembrolizumab treatment for progressive multifocal leukoencephalopathy","volume":"380","author":"Cortese","year":"2019","journal-title":"New Engl J Med"},{"key":"10.1016\/j.coviro.2020.02.005_bib0400","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00415-018-9140-0","article-title":"A controlled inflammation and a regulatory immune system are associated with more favorable prognosis of progressive multifocal leukoencephalopathy","volume":"266","author":"Sanjo","year":"2019","journal-title":"J Neurol"},{"key":"10.1016\/j.coviro.2020.02.005_sbref0405","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.3201\/eid2511.190705","article-title":"Effectiveness of immune checkpoint inhibitors in transplant recipients with progressive multifocal leukoencephalopathy","volume":"25","author":"Medrano","year":"2019","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.coviro.2020.02.005_sbref0410","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJMc1817193","article-title":"Treatment of progressive multifocal leukoencephalopathy with pembrolizumab","volume":"380","author":"Rauer","year":"2019","journal-title":"New Engl J Med"},{"key":"10.1016\/j.coviro.2020.02.005_sbref0415","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1056\/NEJMc1816198","article-title":"Treatment of progressive multifocal leukoencephalopathy with nivolumab","volume":"380","author":"Walter","year":"2019","journal-title":"New Engl J Med"},{"key":"10.1016\/j.coviro.2020.02.005_sbref0420","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000628","article-title":"Pembrolizumab for progressive multifocal leukoencephalopathy due to primary immunodeficiency","volume":"6","author":"K\u00fcpper","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.coviro.2020.02.005_sbref0425","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000627","article-title":"Ineffective treatment of PML with pembrolizumab: exhausted memory T-cell subsets as a clue?","volume":"6","author":"Pawlitzki","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.coviro.2020.02.005_bib0430","doi-asserted-by":"crossref","first-page":"fz374","DOI":"10.1093\/ofid\/ofz374","article-title":"Sustained response and rationale of programmed cell death-1-targeting for progressive multifocal leukoencephalopathy","author":"Audemard-Verger","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.coviro.2020.02.005_bib0435","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1053\/j.seminoncol.2017.06.002","article-title":"A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab","volume":"44","author":"Fessas","year":"2017","journal-title":"Semin Oncol"},{"key":"10.1016\/j.coviro.2020.02.005_sbref0440","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s13365-019-00738-x","article-title":"Progressive multifocal leukoencephalopathy treated with nivolumab","volume":"25","author":"Hoang","year":"2019","journal-title":"J Neurovirol"},{"key":"10.1016\/j.coviro.2020.02.005_bib0445","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1212\/WNL.0b013e3181c0d4a1","article-title":"Determinants of survival in progressive multifocal leukoencephalopathy","volume":"73","author":"Marzocchetti","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.coviro.2020.02.005_bib0450","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s13365-015-0316-4","article-title":"Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy","volume":"21","author":"Dong-Si","year":"2015","journal-title":"J Neurovirol"},{"key":"10.1016\/j.coviro.2020.02.005_bib0455","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1177\/1352458516667241","article-title":"Predictors of severity and functional outcome in natalizumab-associated progressive multifocal leukoencephalopathy","volume":"23","author":"Hoepner","year":"2017","journal-title":"Mult Scler"},{"key":"10.1016\/j.coviro.2020.02.005_bib0460","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1086\/427698","article-title":"Prognostic significance of JC virus DNA levels in cerebrospinal fluid of patients with HIV-associated progressive multifocal leukoencephalopathy","volume":"40","author":"Bossolasco","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coviro.2020.02.005_sbref0465","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.3201\/eid2408.180460","article-title":"Progressive multifocal leukoencephalopathy after treatment with nivolumab","volume":"24","author":"Martinot","year":"2018","journal-title":"Emerging Infect Dis"},{"key":"10.1016\/j.coviro.2020.02.005_bib0470","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/nature22079","article-title":"T-cell invigoration to tumour burden ratio associated with anti-PD-1 response","volume":"545","author":"Huang","year":"2017","journal-title":"Nature"}],"container-title":["Current Opinion in Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625720300067?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625720300067?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T10:00:41Z","timestamp":1761818441000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879625720300067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":94,"alternative-id":["S1879625720300067"],"URL":"https:\/\/doi.org\/10.1016\/j.coviro.2020.02.005","relation":{},"ISSN":["1879-6257"],"issn-type":[{"value":"1879-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Checkpoint inhibitors for the treatment of JC virus-related progressive multifocal leukoencephalopathy","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coviro.2020.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}